Cescato, Renzo; Waser, Beatrice; Fani, Melpomeni; Reubi, Jean-Claude (2011). Evaluation of 177Lu-DOTA-sst2 antagonist versus 177Lu-DOTA-sst2 agonist binding in human cancers in vitro. Journal of nuclear medicine, 52(12), pp. 1886-90. New York, N.Y.: Society of Nuclear Medicine 10.2967/jnumed.111.095778
Full text not available from this repository. (Request a copy)Somatostatin receptor targeting of neuroendocrine tumors using radiolabeled somatostatin agonists is today an established method to image and treat cancer patients. However, in a study using an animal tumor model, somatostatin receptor antagonists were shown to label sst(2)- and sst(3)-expressing tumors in vivo better than agonists, with comparable affinity even though they are not internalized into the tumor cell. In the present study, we evaluated the in vitro binding of the antagonist (177)Lu-DOTA-pNO(2)-Phe-c (DCys-Tyr-DTrp-Lys-Thr-Cys) DTyrNH(2) ((177)Lu-DOTA-BASS) or the (177)Lu-DOTATATE agonist to sst(2)-expressing human tumor samples.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Service Sector > Institute of Pathology |
UniBE Contributor: |
Cescato, Renzo, Waser, Beatrice, Reubi-Kattenbusch, Jean-Claude |
Subjects: |
500 Science > 570 Life sciences; biology 600 Technology > 610 Medicine & health |
ISSN: |
0161-5505 |
Publisher: |
Society of Nuclear Medicine |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:18 |
Last Modified: |
05 Dec 2022 14:05 |
Publisher DOI: |
10.2967/jnumed.111.095778 |
PubMed ID: |
22068898 |
Web of Science ID: |
000298162500023 |
URI: |
https://boris.unibe.ch/id/eprint/5549 (FactScience: 210302) |
Actions (login required)
 |
Edit item |